Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease (CHICO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02625974 |
Recruitment Status :
Active, not recruiting
First Posted : December 9, 2015
Results First Posted : October 29, 2019
Last Update Posted : February 8, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chagas Disease | Drug: Nifurtimox (Lampit, BAYA2502) Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 330 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease |
Actual Study Start Date : | January 27, 2016 |
Actual Primary Completion Date : | July 25, 2018 |
Estimated Study Completion Date : | August 9, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Nifurtimox 60 days / Arm 1
Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
|
Drug: Nifurtimox (Lampit, BAYA2502)
For pediatric subjects with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses. For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses. 60 days of nifurtimox treatment |
Nifurtimox 30 days / Arm 2
Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
|
Drug: Placebo
Matching placebo |
- Percentage of Participants Cured [ Time Frame: At 12 months post-treatment ]
Cure is defined as sero-reduction (in subjects ≥8 months to <18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.
Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).
For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs from the two publications.
- Incidence Rate of Seronegative Conversion for Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.(Part 2) [ Time Frame: Up to 4 years after end of treatment ]Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay [IHA]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1 [ Time Frame: At Visit 1 (before treatment started) ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3 [ Time Frame: Up to 7 days (Visit 3) ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6 [ Time Frame: Up to 30 days (Visit 6) ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8 [ Time Frame: Up to 60 days (Visit 8) end of treatment ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9 [ Time Frame: Up to 90 days (Visit 9) post treatment ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10 [ Time Frame: Up to 240 days (Visit 10) post treatment ]The evaluation was based on clinical examinations.
- Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11 [ Time Frame: Up to 420 days (Visit 11) post-treatment ]The evaluation was based on clinical examinations.
- Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age) [ Time Frame: Up to 90 days (Visit 9) post-treatment ]
- Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test [ Time Frame: Up to 420 days (Visit 11) post-treatment ]The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.
- Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results [ Time Frame: Up to 420 days (Visit 11) post-treatment ]The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results
- Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug
- Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
- Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
- Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
- Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
- Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.
- Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.
- Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.
- Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Clinical significance of abnormal ECG was based on the judgement of the investigator
- Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1) [ Time Frame: Baseline and up to 420 days (Visit 11) post-treatment ]Systolic Blood Pressure
- Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1) [ Time Frame: Baseline and up to 420 days (Visit 11) post-treatment ]Diastolic Blood Pressure
- Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1) [ Time Frame: Baseline and up to 420 days (Visit 11) post-treatment ]Respiratory Rate
- Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1) [ Time Frame: Baseline and up to 420 days (Visit 11) post-treatment ]Heart Rate
- Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1) [ Time Frame: Baseline and up to 420 days (Visit 11) post-treatment ]Temperature
- Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1) [ Time Frame: At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours ]Measured in sub-population.
- Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1) [ Time Frame: At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours ]Measured in sub-population.
- Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1) [ Time Frame: At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours ]Measured in sub-population.
- Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1) [ Time Frame: At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours ]Measured in sub-population.
- Incidence of Seronegative Conversion Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen. (Part 2) [ Time Frame: Up to 4 years after end of treatment ]Measured once per year by two types of assays (recombinant ELISA and IHA) in subjects received at least one dose of 30-day nifurtimox treatment regimen.
- Proportion of Responders With Seronegative Conversion and no Evidence of Cardiomyopathy (Part 2) [ Time Frame: Up to 4 years after end of treatment ]Seronegative conversion measured by two types of assays (recombinant ELISA and IHA). Cardiomyopathy as evaluated by electrocardiogram.
- Antibody Titer in Plasma Over Time in All Subjects (Part 2) [ Time Frame: Up to 4 years after end of treatment ]Measured once per year by recombinant ELISA and total purified antigen ELISA in subjects treated either with the 60- or 30-day nifurtimox treatment regimen.
- Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.
- Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Using frequencies of matches and mismatches to assess agreement
- Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Using frequencies of matches and mismatches to assess agreement
- Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1) [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Using frequencies of matches and mismatches to assess agreement
- Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results [ Time Frame: Up to 420 days (Visit 11) post-treatment ]Sero-reduction is defined as a => 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects => 8 months to < 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects => 8 months to < 18 years of age at randomization; or reactive results in subjects < 8 months of age at randomization.
- Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients [ Time Frame: Up to 420 days (Visit 11) post-treatment ]
Cure is defined as sero-reduction (in subjects => 8 months to < 18 years of age at randomization) or sero-conversion (in all subjects).
Sero-reduction is defined as a => 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Part 1:
- Male and female pediatric subjects aged 0 days to younger than 18 years
- Chagas' disease diagnosed/ confirmed for a) Subjects < 8 months of age at randomization must demonstrate direct observation of Trypanosoma cruzi by concentration test; b) Subjects ≥ 8 months to < 18 years of age at randomization must demonstrate a positive conventional ELISA result for both recombinant ELISA and total purified antigen ELISA
Part 2:
- Male and female subjects who were randomized and received at least one dose of their assigned 60- or 30-day regimen of nifurtimox treatment
Exclusion Criteria:
Part 1:
- Subjects aged 0 to 27 days who, at birth, were pre-term, weighed less than 2500 g, or had a maximum Apgar score < 7 at 5 minutes
- Known evidence of Chagas' disease-related cardiomyopathy/ Chagas' heart disease
- Known evidence of Chagas' disease-related gastrointestinal dysfunction (e.g. megaoesophagus, megacolon, or both) or Chagas' digestive disease
- Serious manifestations of acute Chagas' disease, including myocarditis, meningoencephalitis, or pneumonitis
- Known evidence of Chagas' disease-related damage to the peripheral nervous system or peripheral neuropathy
- Clinically significant psychiatric disorder (e.g. moderate to severe depression, severe anxiety, or psychosis) or epilepsy
- Subjects with contraindications/ warnings to nifurtimox administration, or with conditions that may increase the risk of the undesirable effects of nifurtimox
- Subjects who have had previous treatment with trypanocidal agents or an accepted indication for antiparasitic therapy (e.g. reactivation of Chagas' infection due to immunosuppression by several diseases or treatment with steroids)
- Subjects living in housing conditions where there is no active or effective vector control to Trypanosoma cruzi reinfection as determined by Ministry of Health guidelines in each country
Part 2:
- Subjects who after completing nifurtimox treatment require treatment with an anti-trypanosomal agent
- Subjects living in housing conditions where there is no active or effective vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health guideline of the respective country
- Subjects with clinical manifestations of Chagas' disease-related gastrointestinal dysfunction or serious manifestations of acute Chagas' disease
- Immuno-compromised subjects (e.g. with human immunodeficiency virus or treated with immunosuppressive drugs)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625974
Argentina | |
La Plata, Buenos Aires, Argentina, 1900 | |
Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, 1281 | |
Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1270AAN | |
Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1425AGP | |
Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1425EFD | |
San Salvador de Jujuy, Jujuy, Argentina, 4600 | |
Posadas, Misiones, Argentina | |
Rosario, Santa Fe, Argentina, 2000 | |
Corrientes, Argentina, W3400CBI | |
Formosa, Argentina, P3600HZL | |
La Rioja, Argentina | |
Mendoza, Argentina, 5500 | |
Mendoza, Argentina, 5535 | |
Salta, Argentina, 4400 | |
Salta, Argentina, A4400ESE | |
San Juan, Argentina, 5400 | |
Santiago del Estero, Argentina, 4202 | |
Tucuman, Argentina, 4000 | |
Bolivia | |
Cochabamba, Bolivia | |
Punata, Bolivia | |
Tarija, Bolivia | |
Colombia | |
Barranquilla, Atlántico, Colombia | |
Yopal, Casanare, Colombia, 0 | |
Santa Marta, Magdalena, Colombia, 0 | |
Floridablanca, Santander, Colombia |
Study Director: | Bayer Study Director | Bayer |
Documents provided by Bayer:
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Bayer |
ClinicalTrials.gov Identifier: | NCT02625974 |
Other Study ID Numbers: |
16027 |
First Posted: | December 9, 2015 Key Record Dates |
Results First Posted: | October 29, 2019 |
Last Update Posted: | February 8, 2021 |
Last Verified: | February 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Chagas Disease Trypanosomiasis Euglenozoa Infections Protozoan Infections Parasitic Diseases |
Nifurtimox Trypanocidal Agents Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |